Fungal Infections During and After the SARS-CoV-2 Pandemic: A Retrospective Comparison
Comparative Retrospective Analysis of Fungal Positivity Rates During and Post-SARS-CoV-2 Pandemic Periods
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study aims to retrospectively compare fungal positivity rates by focusing on Candida and Aspergillus species during the SARS-CoV-2 pandemic and in the post-pandemic period. The dataset includes samples collected during the pandemic period (N=623) and the subsequent post-pandemic period (N=818). Fungal positivity rates were calculated and statistically analyzed using chi-square tests, and significance was determined as p<0.01.
During the SARS-CoV-2 pandemic, Candida species showed a positivity rate of 17.36%, while the rate in the post-pandemic period significantly decreased to 9.29% (p=0.002). In contrast, Aspergillus species did not show a significant change in positivity rates between the pandemic (2.22%) and post-pandemic (1.00%) periods (p=0.186, NS).
Overall, the study provides valuable insights into the epidemiology of fungal infections during and after the SARS-CoV-2 pandemic, suggesting possible shifts in fungal pathogen prevalence and healthcare priorities. The findings contribute to the development of targeted healthcare strategies and surveillance measures for fungal infections in the post-pandemic era.
Study Design: Retrospective comparative analysis
Data Analysis: Chi-square tests, p<0.01 considered significant
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey, 34768
- Hisar Hospital Intercontinental
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients over 18 years of age of both genders
Exclusion Criteria:
- Patients under 18 years of age,
- Patients whose demographic, clinical and laboratory data investigated in the study could not be accessed, patients who were diagnosed with fungal infection during hospitalization
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
The percentages of fungus positivity in the SARS CoV-2 pandemic and SARS CoV-2 post-pandemic period
The study was conducted retrospectively, analyzing a total of 1441 patients.
Among these, 623 were during the SARS-CoV-2 pandemic and 818 were in the post-pandemic period.
Fungal positivity rates were calculated separately for different fungal agents including Candida species and Aspergillus.
These rates were presented as percentages and statistically compared between the two periods.
|
Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records.
Fungal positivity rates were calculated based on laboratory results and presented as percentages.
Statistical analyses were performed using the Chi-Square test, and p-values were reported.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fungal positivity rates during the SARS-CoV-2 pandemic period and post-pandemic period
Time Frame: 2020-2024
|
Fungal infection data from samples of patients, 623 of whom were during the SARS-CoV-2 epidemic and 818 of whom were in the post-epidemic period, were retrospectively examined.
Fungal positivity rates for different fungal agents such as Candida species and Aspergillus were calculated separately and compared statistically.
|
2020-2024
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ramazan Gözüküçük, Hisar Hospital Responsible Manager
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ODFUNGAL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.